FLT4 and cancer: In mouse cancer models, administration with anlotinib, a tyrosine kinase inhibitor with anti-lymphangiogenesis activity, and SAR131675, a selective VEGFR-3 inhibitor, effectively decreases LVD and interstitial fluid pressure in tumor tissues, which may improve anti-tumor efficacy by increasing intratumoral accumulation of nanoparticle, macromolecule, and small molecule therapeutic drugs [81].